期刊
DRUG DISCOVERY TODAY
卷 23, 期 10, 页码 1746-1760出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.06.002
关键词
-
资金
- Robert-Bosch Foundation, Stuttgart, Germany
- Interfaculty Centre for Pharmacogenomics and Pharma Research (ICEPHA) Grant Tubingen-tuttgart, Germany
- BMBF 'LiSyM' grant [031L0037]
Solute carrier membrane transporters (SLCs) control cell exposure to small molecule drugs, thereby contributing to drug efficacy and failure and/or adverse effects. Moreover, SLCs are genetically linked to various diseases. Hence, in-depth knowledge of SLC function is fundamental for a better understanding of disease pathophysiology and the drug development process. Given that the model organism Drosophila melanogaster (fruit fly) expresses SLCs, such as for the excretion of endogenous and toxic compounds by the hindgut and Malpighian tubules, equivalent to human intestine and kidney, this system appears to be a promising preclinical model to use to study human SLCs. Here, we systematically compare current knowledge of SLCs in Drosophila and humans and describe the Drosophila model as an innovative tool for drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据